Optopharma is a Hungarian spin-off at Eötvös Loránd University, Budapest.
Core member of the scientific advisory team is András Málnási-Csizmadia, who leads a successful lab in an enterprise-oriented way, with a constantly growing budget.
Optopharma Ltd. promotes the exploitation of research potential in optopharmacology by introducing Molecular Tattoo as a novel drug targeting platform, which was developed in Eötvös Loránd University in collaboration with Miklós Kellermayer and Máté Varga.
The project was funded by the European Research Council both in form of a Starting Grant and a related Proof of Concept Grant and by the National Research, Development and Innovation Fund.
Optopharma also offers improved inhibitors for research, produced in its lab in Hungary.
Optopharma aims to boost life science research and initiate new discoveries by providing research groups the tools and know-how that enable localised treatment by drugs and small molecule inhibitors. Our main products are photoreactive (azidated) derivatives of widely used inhibitors that bind their targets covalently upon irradiation by light. Precise localization is achieved by taking advantage of the small focal spot size of two-photon lasers, which allows drug effects to be confined to single cells, or even sub-cellular areas.